Intraoperative Tumor Margin Identification With ICG Dye Imaging

Launched by MASSACHUSETTS GENERAL HOSPITAL · Feb 8, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the use of a special dye called indocyanine green (ICG) to help surgeons identify and remove tumors more effectively during surgery. The main goal is to see if using ICG can help ensure that all of the tumor is removed, which is important for preventing it from coming back. Researchers will also look at how well patients do after surgery, including the chance of the tumor returning and overall survival rates.

To participate in this study, you need to be at least 18 years old and have a benign (non-cancerous) or malignant (cancerous) bone or soft tissue mass that requires surgery. Unfortunately, if you are pregnant, nursing, or have a severe allergy to certain dyes or have kidney problems, you may not be eligible. If you join the study, you can expect to receive the dye during your surgery, and the doctors will carefully monitor your recovery and health outcomes afterward. This research aims to improve surgical techniques and patient care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients 18 years of age or older who present to Massachusetts General Hospital Department of Orthopaedic Surgery with a benign or malignant bone or soft tissue mass that is consented for surgery during the study period.
• Exclusion Criteria:
• • Pregnant or nursing patients
• • Patients with previously known anaphylaxis to IV contrast or iodine (other allergies may be considered on a case-by-case basis)
• • Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist